Melanóma: vizsgálatok itt: India

1 trial · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 4. fázisNot yet taking people in India
  A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

  Where

  Bhubaneswar, Chennai, Mumbai, Nagpur, Nashik, Navi Mumbai, New Delhi, Pune

  Életkor

  12 év and over

  People

  40

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07459543